NASDAQ:ADIL Adial Pharmaceuticals (ADIL) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free ADIL Stock Alerts $1.64 -0.07 (-4.09%) (As of 08:59 AM ET) Add Compare Share Share Today's Range$1.64▼$1.6450-Day Range$0.83▼$3.2652-Week Range$0.77▼$14.00Volume1,971 shsAverage Volume5.06 million shsMarket Capitalization$6.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Adial Pharmaceuticals alerts: Email Address Adial Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.24% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.60Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.66) to ($12.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.76 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Adial Pharmaceuticals. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.24% of the float of Adial Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAdial Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adial Pharmaceuticals has recently decreased by 91.76%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdial Pharmaceuticals does not currently pay a dividend.Dividend GrowthAdial Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADIL. Previous Next 2.6 News and Social Media Coverage News SentimentAdial Pharmaceuticals has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Adial Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 17 people have searched for ADIL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Adial Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adial Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders14.47% of the stock of Adial Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.41% of the stock of Adial Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adial Pharmaceuticals are expected to decrease in the coming year, from ($1.66) to ($12.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adial Pharmaceuticals is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adial Pharmaceuticals is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdial Pharmaceuticals has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Adial Pharmaceuticals Stock (NASDAQ:ADIL)Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Read More ADIL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADIL Stock News HeadlinesApril 24, 2024 | uk.investing.comAdial Pharmaceuticals secures new addiction treatment patentApril 22, 2024 | finanznachrichten.deAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark OfficeApril 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 22, 2024 | benzinga.comEXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US PatentApril 22, 2024 | globenewswire.comAdial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark OfficeApril 11, 2024 | msn.comWhy Bitcoin-Linked MicroStrategy Along With Adial Pharmaceuticals, Alpine Immune Sciences, Marin Software, And Tesla Are On Investors' Radars TodayApril 11, 2024 | msn.comDow Falls Over 1%; US Inflation Rate Accelerates In MarchApril 10, 2024 | marketwatch.comAdial Pharmaceuticals Shares Rise 78% After Positive Trial Data for AD04April 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 10, 2024 | msn.comAdial stock rallies 81% on data for alcohol abuse drugApril 10, 2024 | investorplace.comWhy Is Adial Pharmaceuticals (ADIL) Stock Up 59% Today?April 10, 2024 | msn.comEXCLUSIVE: Adial Pharmaceuticals' Potential Treatment For Alcohol Use Disorder Shows Encouraging Safety, Patient ComplianceApril 10, 2024 | finance.yahoo.comAdial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use DisorderApril 10, 2024 | globenewswire.comAdial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use DisorderApril 2, 2024 | globenewswire.comAdial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business UpdateMarch 19, 2024 | investing.comAdial Pharmaceuticals Inc (ADIL)March 16, 2024 | finance.yahoo.comMASI Apr 2024 120.000 callMarch 16, 2024 | finance.yahoo.comMASI Apr 2024 125.000 putMarch 11, 2024 | benzinga.comPeering Into Adial Pharmaceuticals's Recent Short InterestMarch 1, 2024 | globenewswire.comAdial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross ProceedsMarch 1, 2024 | investing.comAdial Pharmaceuticals secures new patent for AD04 drugFebruary 28, 2024 | msn.comWhy Adial Pharmaceuticals Stock Is Blasting OffFebruary 28, 2024 | finanznachrichten.deAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark OfficeFebruary 28, 2024 | finance.yahoo.comEXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Lead Product For Alcohol Use DisorderFebruary 28, 2024 | globenewswire.comAdial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark OfficeFebruary 15, 2024 | finanznachrichten.deAdial Pharmaceuticals, Inc.: Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20February 15, 2024 | finance.yahoo.comAdial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20See More Headlines Receive ADIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2021Today4/25/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ADIL CUSIPN/A CIK1513525 Webwww.adialpharma.com Phone(434) 422-9800FaxN/AEmployees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-250.52% Return on Assets-183.24% Debt Debt-to-Equity RatioN/A Current Ratio4.90 Quick Ratio4.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.46 per share Price / Book0.70Miscellaneous Outstanding Shares4,050,000Free Float3,468,000Market Cap$6.93 million OptionableNo Data Beta1.48 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Joseph A. M. Truluck M.B.A. (Age 46)MBA, CFO, Treasurer & Secretary Comp: $279.7kMr. Tony Goodman (Age 60)COO & Director Comp: $59kDr. Bankole A. Johnson DSc (Age 64)FRCPsych, M.D., M.Phil, Ph.D., Founder & Chief Medical Officer Comp: $375kMr. John R. Martin J.D.General CounselMr. Alex LugovoyChief Business OfficerDr. Jack W. Reich Ph.D. (Age 75)Head of Regulatory Comp: $17.01kMr. Mark H. PeikinChief Strategy Officer & Chief Development OfficerMs. Catherine FratilaControllerMore ExecutivesKey CompetitorsYumanity TherapeuticsNASDAQ:YMTXCadrenal TherapeuticsNASDAQ:CVKDProtagenic TherapeuticsNASDAQ:PTIXTenax TherapeuticsNASDAQ:TENXClever LeavesNASDAQ:CLVRView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 159,000 shares on 2/13/2024Ownership: 9.578%Kevin SchuylerBought 700 shares on 9/29/2023Total: $1,918.00 ($2.74/share)View All Insider TransactionsView All Institutional Transactions ADIL Stock Analysis - Frequently Asked Questions How have ADIL shares performed in 2024? Adial Pharmaceuticals' stock was trading at $1.86 at the start of the year. Since then, ADIL stock has decreased by 8.1% and is now trading at $1.71. View the best growth stocks for 2024 here. Are investors shorting Adial Pharmaceuticals? Adial Pharmaceuticals saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 8,700 shares, a decrease of 91.8% from the March 15th total of 105,600 shares. Based on an average trading volume of 3,830,000 shares, the short-interest ratio is currently 0.0 days. Approximately 0.2% of the company's shares are sold short. View Adial Pharmaceuticals' Short Interest. When is Adial Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our ADIL earnings forecast. How were Adial Pharmaceuticals' earnings last quarter? Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) released its quarterly earnings results on Wednesday, August, 11th. The company reported ($6.25) EPS for the quarter, missing the consensus estimate of ($5.00) by $1.25. When did Adial Pharmaceuticals' stock split? Shares of Adial Pharmaceuticals reverse split on the morning of Monday, August 7th 2023. The 1-25 reverse split was announced on Monday, August 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Adial Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Aytu BioPharma (AYTU), T2 Biosystems (TTOO), AIM ImmunoTech (AIM), Tandem Diabetes Care (TNDM), vTv Therapeutics (VTVT), Acasti Pharma (ACST) and Adamis Pharmaceuticals (ADMP). When did Adial Pharmaceuticals IPO? Adial Pharmaceuticals (ADIL) raised $8 million in an IPO on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager. How do I buy shares of Adial Pharmaceuticals? Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADIL) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
